Cencora, Inc. (LON:0HF3)
242.09
-0.99 (-0.41%)
At close: Feb 21, 2025
Cencora Revenue
Cencora had revenue of $81.49B USD in the quarter ending December 31, 2024, with 12.78% growth. This brings the company's revenue in the last twelve months to $303.19B, up 11.64% year-over-year. In the fiscal year ending September 30, 2024, Cencora had annual revenue of $293.96B with 12.12% growth.
Revenue (ttm)
$303.19B
Revenue Growth
+11.64%
P/S Ratio
n/a
Revenue / Employee
$6.59M
Employees
46,000
Market Cap
37.03B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 293.96B | 31.79B | 12.12% |
Sep 30, 2023 | 262.17B | 23.59B | 9.89% |
Sep 30, 2022 | 238.59B | 24.60B | 11.50% |
Sep 30, 2021 | 213.99B | 24.09B | 12.69% |
Sep 30, 2020 | 189.89B | 10.30B | 5.74% |
Sep 30, 2019 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 30, 2016 | Pro | Pro | Pro |
Sep 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Cencora News
- 16 days ago - Cencora Announces Common Share Repurchase From Walgreens Boots Alliance - Business Wire
- 16 days ago - Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds - Business Wire
- 17 days ago - McKesson, AmerisourceBergen get judge to toss price-fixing lawsuit - Seeking Alpha
- 17 days ago - Cencora Reinforces Efforts to Strengthen Pharmaceutical Supply Chain with Expansion of Drug Shortages Mitigation Program - Business Wire
- 18 days ago - Cencora (COR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Cencora raises 2025 profit forecast on specialty drug demand - Reuters
- 18 days ago - Cencora Reports Fiscal 2025 First Quarter Results - Business Wire
- 27 days ago - Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients - Business Wire